Mesothelin and CD137 binding molecules
US12319739B2 · kind B2 · utility
0Cited by
21References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2019 |
| Grant date | Jun 3, 2025 |
| Priority date | — |
| Expiry date | Apr 25, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of the antibody molecule. The antibody molecules find application in the treatment of cancer, for example.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.